ANT-GROUP-DIGITAL
3.11.2022 10:19:44 CET | Business Wire | Press release
Ant Group Digital Technologies, a digital technology provider under Ant Group, today unveiled its blockchain storage engine “LETUS” (Log-structured Efficient Trusted Universal Storage) at the Apsara Conference 2022 in Hangzhou.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221103005680/en/
Yan Ying, Technical Director of AntChain, unveiled the LETUS at the Apsara Conference (Photo: Business Wire)
LETUS, which was developed and designed by the AntChain team, will increase the effectiveness and lower the storage costs for blockchain networks.
Blockchain is a distributed peer-to-peer network, with each node storing data such as blocks and states. The LETUS storage engine is deployed at each blockchain node to provide trusted storage support. At the same time, LETUS has the advantages in performance, large scale workloads handling capability, cost, and resource efficiency through Smart Thermo-control Tiering and Boundary Scan Based Batch Pruning.
“As more and more digital assets are stored on the blockchain, storage capacity and efficiency has increasing impact on the overall performance of blockchain platforms, including transaction speeds and operational costs,” said Yan Ying, Technical Director of AntChain. “Compared to current mainstream industry solutions, LETUS can improve storage throughput by 15 times, reduce latency by 90%, and save disk bandwidth and space usage by 95% and 60%, respectively."
LETUS has already been deployed and running in Topnod, a digital collectibles platform powered by AntChain. It has helped the platform greatly improve performance and reduce storage costs by about 75%.
“For the many industries undergoing digital transformations, mutual trust between companies and customers is increasingly important. At Ant, we have been investing in research and development for blockchain and other digital technologies that help to increase both trust and security,” said Geoff Jiang, President of Digital Technology Business Group at Ant Group. “We remain focused on the technological breakthroughs that create a trusted digital network to improve industrial collaboration and allow us to use our innovative products and services to better serve the real economy.”
During the conference, Ant Group Digital Technologies also released the:
- 4.0 version of mPaaS, its one-stop mobile development solution;
- 2.0 version of its Morse MPC (Multi-party Computation) platform;
- 4.0 version of SOFAStack, its cloud-native PaaS platform;
- 4.0 version of OceanBase Community Edition, its distributed database; and
- other security products.
In the past two years, Ant Group Digital Technologies has also released a number of blockchain-related products and solutions, including:
- AntChain Station, the all-in-one workstation;
- Blockchain Transmission Network (BTN), a high-speed, long-distance blockchain communication technology;
- Module-as-a-Service (MaaS) integrated computing module for simplified blockchain deployment;
- FAIR, the data privacy collaboration platform; and
- T1 security chip, its self-developed blockchain-powered security chip.
Many of these cutting-edge solutions have been successfully deployed by Chery Automobile, Zhejiang Huatie Emergency Equipment Science and Technology and other industry partners.
Ant Group Digital Technologies
Ant Group Digital Technologies continues to promote the development and application of digital technology, introducing leading products like AntChain, OceanBase, SOFAStack, and mPaaS based on its expertise in blockchain, privacy computing, security technology, and distributed database. Ant Group Digital Technologies is committed to working with partners across different industries to support the small and medium-sized financial institutions in their digital transformation, enable SMEs in the service industry to operate digitally and facilitate digital collaboration across industries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005680/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
